Literature DB >> 29486419

Cross-sectional cause of death comparisons for stimulant and opioid mortality in San Francisco, 2005-2015.

Caitlin Turner1, Dharsan Chandrakumar2, Christopher Rowe3, Glenn-Milo Santos4, Elise D Riley5, Phillip O Coffin6.   

Abstract

BACKGROUND: Opioids and stimulants (e.g., cocaine or methamphetamine/amphetamine [MAMP]) are major contributors to acute substance toxicity deaths. Causes of stimulant death have received little attention. We sought to characterize and compare causes of death and significant contributing conditions among persons who died from acute opioid, cocaine, or MAMP toxicity.
METHODS: We identified all opioid, cocaine, or MAMP deaths in San Francisco from 2005 to 2015 through the California Electronic Death Reporting System. Multivariable logistic regression analyses were used to estimate associations between acute substance toxicity deaths (opioid versus stimulant; cocaine versus MAMP), additional reported causes of death, and significant contributing conditions most often linked to opioid and stimulant use.
RESULTS: From 2005-2015, there were 1252 opioid deaths and 749 stimulant deaths. Cocaine accounted for most stimulant deaths. Decedents with cardiac or cerebral hemorrhage deaths had higher adjusted odds of death due to acute stimulant toxicity versus acute opioid toxicity (aOR = 4.79, 95%CI = 2.88-7.96, p < 0.01; aOR = 58.58, 95%CI = 21.06-162.91, p < 0.01, respectively); no statistically significant associations were found for cocaine compared to MAMP deaths. Significant contributing cardiac conditions were associated with higher adjusted odds of stimulant compared to opioid (aOR = 1.46, 95%CI = 1.19-1.79, p < 0.01) and cocaine compared to MAMP death (aOR = 1.66, 95%CI = 1.13-2.45, p = .01).
CONCLUSIONS: Stimulant compared to opioid deaths tended to involve cardiac or cerebrovascular causes of death, and cocaine deaths were more likely than MAMP deaths to involve significant contributing cardiac conditions. Mounting evidence suggests that stimulant use be considered a cardio/cerebrovascular risk factor and clinical care be adjusted to address this heightened risk.
Copyright © 2018 Elsevier B.V. All rights reserved.

Entities:  

Keywords:  Acute substance toxicity deaths; Cocaine mortality; Methamphetamine/amphetamine mortality; Multiple causes of death; Opioid mortality; Stimulant mortality

Mesh:

Year:  2018        PMID: 29486419      PMCID: PMC6474784          DOI: 10.1016/j.drugalcdep.2017.12.030

Source DB:  PubMed          Journal:  Drug Alcohol Depend        ISSN: 0376-8716            Impact factor:   4.492


  14 in total

1.  Sociodemographic factors and social determinants associated with toxicology confirmed polysubstance opioid-related deaths.

Authors:  Joshua A Barocas; Jianing Wang; Brandon D L Marshall; Marc R LaRochelle; Amy Bettano; Dana Bernson; Curt G Beckwith; Benjamin P Linas; Alexander Y Walley
Journal:  Drug Alcohol Depend       Date:  2019-05-08       Impact factor: 4.492

2.  Interoceptive attention in opioid and stimulant use disorder.

Authors:  Jennifer L Stewart; Sahib S Khalsa; Rayus Kuplicki; Maria Puhl; Martin P Paulus
Journal:  Addict Biol       Date:  2019-10-16       Impact factor: 4.280

3.  A Chronic Condition Disguised as an Acute Event: the Case for Re-thinking Stimulant Overdose Death.

Authors:  Elise D Riley; Priscilla Y Hsue; Phillip O Coffin
Journal:  J Gen Intern Med       Date:  2022-06-17       Impact factor: 6.473

4.  Hypocretin/Orexin Interactions with Norepinephrine Contribute to the Opiate Withdrawal Syndrome.

Authors:  Ronald McGregor; Ming-Fung Wu; Brent Holmes; Hoa Anh Lam; Nigel T Maidment; Joseph Gera; Akihiro Yamanaka; Jerome M Siegel
Journal:  J Neurosci       Date:  2021-12-01       Impact factor: 6.709

Review 5.  Methamphetamine and the risk of pulmonary arterial hypertension.

Authors:  Ramon L Ramirez; Vinicio De Jesus Perez; Roham T Zamanian
Journal:  Curr Opin Pulm Med       Date:  2018-09       Impact factor: 3.155

6.  Patterns, contexts, and motivations for polysubstance use among people who inject drugs in non-urban settings in the U.S. Northeast.

Authors:  Pablo K Valente; Angela R Bazzi; Ellen Childs; Peter Salhaney; Joel Earlywine; Jennifer Olson; Dea L Biancarelli; Brandon D L Marshall; Katie B Biello
Journal:  Int J Drug Policy       Date:  2020-09-07

7.  Non-fatal stimulant overdose among homeless and unstably housed women in San Francisco, California.

Authors:  Thibaut Davy-Mendez; Eric Vittinghoff; Samantha E Dilworth; Leslie W Suen; Carl Braun; Phillip O Coffin; Derek D Satre; Elise D Riley
Journal:  Drug Alcohol Depend       Date:  2021-09-22       Impact factor: 4.492

8.  Characterizing stimulant overdose: A qualitative study on perceptions and experiences of "overamping".

Authors:  Manal Mansoor; Ryan McNeil; Taylor Fleming; Allison Barker; Sheila Vakharia; Kimberly Sue; Andrew Ivsins
Journal:  Int J Drug Policy       Date:  2022-01-31

9.  Trends in Poly Drug Use-associated Deaths based on Confirmed Analytical Toxicology Results in Tehran, Iran, in 2011-2016.

Authors:  Maryam Akhgari; Fariba Sardari-Iravani; Masoud Ghadipasha
Journal:  Addict Health       Date:  2021-01

Review 10.  Bouncing back: Brain rehabilitation amid opioid and stimulant epidemics.

Authors:  Jennifer L Stewart; April C May; Martin P Paulus
Journal:  Neuroimage Clin       Date:  2019-11-05       Impact factor: 4.881

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.